The effect of a polyherbal oral formulation in the management of essential hypertension: an open label, pilot clinical study

Rohit Sane; Suhas Dawkhar; Pranit Ambulkar; Rahul Mandole

doi:10.18203/2319-2003.ijbcp20182694

Authors

Rohit Sane Department of Research and Development, Madhavbaug Cardiac Care Clinics and Hospitals. Mumbai, Maharashtra, India http://orcid.org/0000-0003-3366-085X
Suhas Dawkhar Department of Patient Engagement, Madhavbaug Cardiac Care Clinics and Hospitals. Mumbai, Maharashtra, India
Pranit Ambulkar Department of Research and Development, Madhavbaug Cardiac Care Clinics and Hospitals. Mumbai, Maharashtra, India
Rahul Mandole Department of Research and Development, Madhavbaug Cardiac Care Clinics and Hospitals. Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20182694

Keywords:

Capsule artyl, Essential hypertension, Systolic blood pressure

Abstract

Background: Effective control of blood pressure in patients with hypertension decreases cardiovascular mortality. However, many hypertensives are unresponsive to standard antihypertensive treatment. Research has found anti-hypertensive potential in the Ayurvedic drugs Brahmi (Bacopa monnieri) and Shunthi (Zingiber officinale). Hence, a pilot study was conducted to evaluate the efficacy and safety of Capsule Artyl (the oral formulation of Brahmi and Shunthi) as a treatment option in hypertensive subjects.

Methods: There were 30 hypertensive subjects attending out-patient departments of clinics in Maharashtra, India were enrolled in this four-week, open label, single arm study. All subjects received capsule Artyl (500mg) twice a day orally daily. The mean systolic (SBP) and diastolic blood pressure (DBP) on days 1 and 28 of the study were compared along with the mean arterial pressure (MAP).

Results: The mean SBP was significantly lesser on day 28 (141.86±12.54mm Hg) as compared to the mean SBP recorded on day 1 (155.48±19.37mm Hg) (p<0.001). The mean DBP on day 28 (89.66±6.8mm Hg) was lesser than that on day 1 (90.34±7.44mm Hg) but this difference was not statistically significant (p>0.05). There was a significant decrease in the mean value of MAP on day 28 (107.06±7.03mm Hg) as compared to that on day 1 (112.06±10.75mm Hg) (p<0.01).

Conclusions: Capsule Artyl significantly decreased the BP in hypertensive patients, without any adverse effects. Controlled trials are needed to confirm the positive outcome of this promising herbal formulation in hypertensive patients.

Metrics

Metrics Loading ...

References

Tiwaskar M. Hypertension Control in India: Are we there Yet? OR Uncontrolled and Resistant Hypertension: The Indian Perspective. J Assoc Physicians India. 2016;64(7):11-2.

Indian Guidelines on Hypertension-III. J Clin Prev Cardiol. 2013;3:128-61.

Mohan S, Campbell N, Chockalingam A. Time to eﬀectively address hypertension in India. Indian J Med Res. 2013;137:627-31.

Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA. 2003;289:2073-82.

Anchala R, Kannuri NK, Pant H, Khan H, Franco OH, Di Angelantonio E, et al. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens. 2014;32:1170-7.

Hussain GM, Mishra D, Singh PN, Rao ChV, Kumar V. Ethnopharmacological review of native traditional medicinal plants for brain disorders. Pharmacognosy review. 2007;1(1):19-29.

Kamkaew N, Scholfield C, Ingkaninan K, Maneesai P, Parkington H, Tare M, et al. Bacopa monnieri and its constituents is hypotensive in anaesthetized rats and vasodilator in various artery types. J of Ethnopharm. 2011;137(1):790-5.

Mishra D, Tubaki B. The effect of Brahmi vati and Sarpagandha Ghana vati in management of essential hypertension - A randomized, double blind, controlled clinical study. Journal of Ayurveda and Integrative Medicine; 2017.

Ghayur M, Gilani A. Ginger Lowers Blood Pressure Through Blockade of Voltage-Dependent Calcium Channels. J of Cardio Pharmac. 2005;45(1):74-80.

Torabi M, Naeemzadeh F, Ebrahimi V, Taleschian-Tabrizi N, Pashazadeh F, Nazemie H. The Effect of Zingiber Officinale (Ginger) On Hypertension; A Systematic Review of Randomised Controlled Trials. BMJ Open. 2017;7(0):A1-A78.

Kapoor A, Kumar A, Mahapatra AK, Chauhan G. Open clinical trial of a polyherbal compound M-Sarpagandhamishran in essential hypertension: a pilot study. Int J Res Ayurveda Pharm. 2014;5(5):594-9.

Wang Y, Yu H, Zhang X, Feng Q, Guo X, Li S, et al. Evaluation of daily ginger consumption for the prevention of chronic diseases in adults: a cross-section study. Nutrition; 2016.

Shaban MI, El-Gahsh NFA, El-Said A, El-Sol H. Ginger: It's Effect on Blood Pressure among Hypertensive Patients. IOSR Journal of Nursing and Health Science. 2017;6(5):79-86.

Akinyemi A, Ademiluyi A, Oboh G. Inhibition of Angiotensin-1-Converting Enzyme Activity by Two Varieties of Ginger (Zingiber officinale) in Rats Fed a High Cholesterol Diet. Journal of Medicinal Food. 2014;17(3):317-23.